Ridgetech Inc. RDGT
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-17.21
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $132.2M | $120.0M | $124.0M | $120.2M | $164.4M | $133.1M | $117.3M | — | — |
| Cost of revenue | $127.4M | $116.1M | $119.1M | $116.6M | $127.9M | $133.1M | $91.8M | — | — |
| Gross profit | $4.8M | $3.8M | $4.9M | $3.6M | $36.5M | $29.2M | $25.5M | — | — |
| SG&A | $3.6M | $3.3M | $3.3M | $5.1M | $8.2M | $7.0M | $8.1M | — | — |
| Total operating expenses | $6.6M | $4.9M | $4.3M | $16.8M | $39.2M | $38.1M | $32.5M | — | — |
| Operating income | -$1.9M | -$1.0M | $596.1K | -$13.2M | -$2.7M | -$8.8M | -$7.0M | — | — |
| Interest expense | $67.1K | $92.8K | $197.8K | $31.6K | $401.9K | $707.9K | $698.5K | — | — |
| Pre-tax income | -$1.3M | -$950.7K | -$827.1K | -$15.4M | -$2.1M | -$8.3M | -$6.4M | — | — |
| Income tax | $99.1K | $503.5K | $41.4K | $394.5K | $1.1M | $31.6K | $16.3K | — | — |
| Net income | -$1.3M | $10.2M | -$4.2M | -$21.1M | -$3.2M | -$8.1M | -$5.8M | — | — |
| EPS, basic | -17.21 | 275.87 | -439.78 | -41.46 | -18.35 | -2.39 | -2.16 | — | — |
| EPS, diluted | -17.21 | 275.87 | -439.78 | -41.46 | -18.35 | -2.39 | -2.16 | — | — |
| Shares, diluted (wtd. avg.) | 72,668 | 36,954 | 9,628 | 509,828 | 173,966 | 3.4M | 2.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.9M | $12.8M | $32.9M | $31.6M | $35.3M | $34.7M | $31.0M | $24.7M | $79.6K |
| Receivables | $32.5M | $27.8M | $6.0M | $14.1M | $16.7M | $13.4M | — | — | — |
| Inventory | $8.3M | $9.8M | $9.1M | $15.3M | $16.0M | $17.0M | — | — | — |
| Total current assets | $64.6M | $59.7M | $69.7M | $64.5M | $75.4M | $72.2M | — | — | — |
| Property, plant and equipment | $5.7K | $8.9K | $8.4K | $5.1M | $5.9M | $6.5M | — | — | — |
| Goodwill | $1.5M | $1.5M | — | — | — | — | — | — | — |
| Other intangibles | $3.0M | $3.3M | $1.3M | $3.2M | $3.5M | $3.5M | — | — | — |
| Total assets | $69.0M | $64.5M | $95.1M | $91.0M | $106.4M | $106.3M | — | — | — |
| Accounts payable | $22.8M | $19.7M | $30.6M | $27.0M | — | — | — | — | — |
| Short-term debt | — | — | $277.0K | — | — | $762.3K | — | — | — |
| Total current liabilities | $27.9M | $34.4M | $74.4M | $66.5M | $74.4M | $64.9M | — | — | — |
| Long-term debt | — | — | — | — | — | $1.9M | — | — | — |
| Total liabilities | $28.3M | $34.8M | $80.8M | $74.3M | $83.6M | $81.9M | — | — | — |
| Retained earnings | -$64.6M | -$63.3M | -$73.5M | -$69.3M | -$48.1M | -$44.9M | — | — | — |
| Total equity | $40.8M | $29.6M | $14.3M | $16.7M | $22.7M | $24.4M | $18.8M | $17.0M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.4M | $1.2M | -$3.2M | -$3.3M | -$5.4M | -$62.3K | -$6.9M | — | — |
| Depreciation and amortisation | $363.7K | $1.1M | $790.4K | $718.0K | $1.3M | $1.8M | $2.1M | — | — |
| Stock-based compensation | — | — | — | $10.4M | — | $3.9M | $34.6K | — | — |
| Capital expenditure | $449 | $155.4K | $330.7K | $118.3K | $90.0K | $126.8K | $656.3K | — | — |
| Investing cash flow | -$449 | -$18.1M | -$2.0M | -$316.1K | -$306.1K | -$2.0M | -$4.8M | — | — |
| Financing cash flow | -$29.7K | $1.5M | $8.0M | $2.4M | $4.8M | $3.1M | $19.0M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-083638.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2014 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $117.3M | $133.1M | $164.4M | $120.2M | $124.0M | $120.0M | $132.2M |
| Gross profit | — | — | $25.5M | $29.2M | $36.5M | $3.6M | $4.9M | $3.8M | $4.8M |
| Net income | — | — | -$5.8M | -$8.1M | -$3.2M | -$21.1M | -$4.2M | $10.2M | -$1.3M |
Others in SIC 5912
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CVS | CVS HEALTH Corp | $119.55B | 67.2x | 7.8% |
| PETS | PETMED EXPRESS INC | $26.4M | — | -21.1% |
| YI | 111, Inc. | — | — | -9.0% |
| GRDN | Guardian Pharmacy Services, Inc. | — | — | 17.9% |